{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:27:19Z","timestamp":1783636039881,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":218,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.lrr.2020.100220","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T21:17:48Z","timestamp":1596835068000},"page":"100220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Isotretinoin is active in the initial management of acute pro-myelocytic leukemia"],"prefix":"10.1016","volume":"14","author":[{"given":"Husain Y.","family":"Alkhaldy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Assiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaila","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Owaidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2020.100220_bib0001","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the FrenchAmerican-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lrr.2020.100220_bib0002","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.1990.8.11.1913","article-title":"The unique aspects of acute promyelocytic leukemia","volume":"8","author":"Stone","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2020.100220_bib0003","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood.V79.3.543.543","article-title":"Reassessing the hemostatic disorder associated with acute promyelocitic leukemia","volume":"79","author":"Tallman","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2020.100220_bib0004","unstructured":"Kotiah S.D., Besa E.C. Acute promyelocytic leukemia: practice essentials, background, pathophysiolog[Internet]. 2019 [accessed 3rd December 2019]. Available at:https:\/\/emedicine.medscape.com\/article\/1495306-overview."},{"key":"10.1016\/j.lrr.2020.100220_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0268-960X(02)00075-9","article-title":"The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease","volume":"17","author":"Mistry","year":"2003","journal-title":"Blood Rev."},{"key":"10.1016\/j.lrr.2020.100220_bib0006","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood.V93.10.3167.410k44_3167_3215","article-title":"Deconstructing a disease: rAR\u03b1, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia","volume":"93","author":"Melnick","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2020.100220_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-009-0060-0","article-title":"Acute promyelocytic leukaemia in children","volume":"11","author":"Gregory","year":"2009","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.lrr.2020.100220_bib0008","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.lrr.2020.100220_bib0009","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V62.6.1211.1211","article-title":"Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations","volume":"62","author":"Flynn","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2020.100220_bib0010","article-title":"Reversible inhibition by retinoids of 3-methylcholanthrene-induced neoplastic transformation in C3 HI OT\u2019\/ clone 8 cells","volume":"39","author":"Merriman","year":"1979","journal-title":"Cancer Res."},{"key":"10.1016\/j.lrr.2020.100220_bib0011","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1073\/pnas.77.5.2936","article-title":"Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid","volume":"77","author":"Breitman","year":"1980","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.lrr.2020.100220_bib0012","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.42.6.753","article-title":"Tissue changes following deprivation of fat soluble A vitamin","volume":"42","author":"Wolbach","year":"1925","journal-title":"J. Exp. Med."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048920300261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048920300261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:23Z","timestamp":1761959303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048920300261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":12,"alternative-id":["S2213048920300261"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2020.100220","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isotretinoin is active in the initial management of acute pro-myelocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2020.100220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100220"}}